Thursday, 16 Aug 2018

You are here

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

This panel is advisory to the FDA and no decision has yet been made on drug approval; although the FDA usually follows advisory panel recommendations.  

Tofacitinib is currently approved for use in rheumatoid arthritis and psoriatic arthritis at a dose of 5 mg bid (or 11 mg once daily).  This new recommendation for approval of the 10 mg bid dose would be the first approval of "high dose" Xeljanz.  Although higher doses were studied and petitioned for by Pfizer, the FDA has only approved the lower dose noting no substantial efficacy advantage while questioning the safety of the higher dose.

If approved, tofacitinib will be the first JAK inhibitor and the first oral therapy for patients with active ulcerative colitis.  It would also be the 2nd approval for tofacitinib within a 6 month period.

The company proposed an initial 8 week regimen of tofacitinib 10 mg BID for induction to be followed by tofacitinib 5 mg BID for maintenance.  But the panel voted 8-7 against a post-marketing efficacy study comparing a tofacitinib 10 mg BID continuous dosing regimen versus a regimen of tofacitinib 10 mg BID induction and 5 mg BID maintenance.

A decision on this application is expected by June 2018.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

IL-1 Suppression May Improve Dilated Cardiomyopathy


Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.